Roche Sees Return on $310M Investment with Alnylam’s Phase II Hypertension Win
BioSpace
JULY 8, 2023
The RNAi therapy, which the companies are co-developing and commercializing, reduced blood pressure in hypertensive patients with high cardiovascular risk by 15 mmHg over placebo.
Let's personalize your content